In this issue:
OnabotulinumtoxinA for the prevention of chronic migraine
MIDAS reduction at 3 months and erenumab treatment outcome
Preventive treatment can reverse cognitive impairment in chronic migraine
Serum CGRP in migraine patients using erenumab
Functional connectivity and structural changes of thalamic subregions in episodic migraine
mAbs against CGRP and its receptor for migraine patients with prior preventive treatment failure
Quantity changes in acute headache medication use for chronic migraine treated with eptinezumab
Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups
Rapid resolution of migraine symptoms after preventive treatment with eptinezumab during a migraine attack
Leukocyte inflammatory phenotype and function in migraine
Please login below to download this issue (PDF)